FDA Approves Shire’s New Gaucher Drug

MBBP client Shire Human Genetic Therapies, a global specialty biopharmaceutical company, announced last week that the U.S. Food and Drug Administration has approved their new drug VPRIV. VPRIV is a human cell line derived enzyme replacement therapy (ERT) meant to help treat Type 1 Gaucher disease. Shire’s drug has been prescribed to patients before its approval on an emergency basis for several months due to the shortage of Genzyme Corporation’s Cerezyme.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s